Earnings Est Current Qtr.
Jun 16 Next Qtr.
Sep 16 Current Year
Dec 16 Next Year
Avg. Estimate 0.58 0.60 2.24 2.66
Beyond measuring blood flow, pressure, oxygen levels and other vital signs in the cardiac catheterization lab, current hemodynamic recording systems are an integral part of clinical reporting. Hemodynamic data from newer systems helps auto-completion of data fields in procedure reports, can automate gathering registry data, and can help interface cath lab patient data with the patient’s electronic medical record (EMR).
In the cath lab, the hemodynamic system is at the core of all procedures, including cardiac procedures, interventional radiology, vascular surgery and electrophysiology (EP). Newer-generation hemodynamic monitoring systems have interfaces to help document all types of procedures. This may include charting, device usage, specific site identification, fractional flow reserve (FFR), sheath exchanges, and automatic timers to record balloon inflation time and pressures applied. The data gathered by the system helps speed workflow by automatically generating reports and auto-fills report fields and billing information. Interfaces also display and record waveforms. Many features of these systems can be customized to each cath lab’s needs. Most also contain a coronary tree diagram for procedure documentation.
need a write off ...:)
Palatin had no revenues this past quarter.
Press releases are vague.
Losses for the past three years are over $51 million.
Time to review another drug company. Palatin Technologies (NYSEMKT:PTN) has been extremely volatile in recent weeks. But why?
Ever since an FDA advisory committee recommended approving Sprout Pharmaceuticals' flibanserin drug for Hyperactive Sexual Desire Disorder (HSDD) Palatin has been skyrocketing. The media often refers to flibanserin as female Viagra.
So lets examine the activity surrounding the FDA approval. On June 4, 2015 - the day before the FDA ruling was announced, Palatin stock closed at $0.90 on 105,400 shares. After the market closed, Palatin issued a press release where it mentioned the FDA's recommendation letter for approval of flibanserin. The headline of the article was"Palatin Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder" (HSDD). You will notice that nowhere in the headline (nor the content of the entire article) is it mentioned that flibanserin IS NOT a drug owned by Palatin. As a result, traders naturally assumed that the drug was indeed owned by Palatin and immediately after the press release was issued the stock rallied to over $1.00. The next day (June 5, 2015) Palatin stock opened at $1.41 and rallied to $1.58. As information was released (via internet stock message boards) and it became evident by astute traders that another company (privately held Sprout Pharmaceuticals) owned the rights to flibanserin, PTN stock price eroded for the remainder of the day and closed on the low of the day at $1.00. Volume for June 5, 2015 was 32,408,000 shares. Not only is that a whopping 3200% increase in volume, it is over 75% of the 42 million shares outstanding.
So why was the press release put out by Palatin? The most innocent reason I can come up with was it was done in an effort to attract attention to the fact that Palatin too has a drug in the pipeline to fight HSDD called bremelanotide. If that is the case, it is a poor PR job on behalf of Palatin management. The reality of the situation is that in the pharmaceutical industry the first drug to be approved garners an overwhelming percentage (often over 80-90%) of sales for the illness they are curing. By flibanserin being the first drug to potentially make it to market, the market for Palatin's own drug (bremelanotide) will be miniscule.
I have pondered the logic of this press release for over a week and it still makes no sense to me. Hopefully someone else can articulate a viable reason. Palatin shares closed June 17, 2015 at $1.03 a share.
The two top executives received base salaries of $450,000 and $410,000 in 2014. Their total compensation for 2014 was $964,000 and $843,000. This compensation is for a company that had net losses of $13.928 million in 2014, $20.862 million in 2013 and $17.253 million in 2012. Normally I use a salary to sales ratio to evaluate if a Company's compensation is out of line. Given the fact that Palatin has no revenues this is a useless metric. Using sales to profits is another metric that an be used to measure performance. Once again, this metric is useless because Palatin has no profits. If there was at least a change in the loss which resulted to near break even results I could understand the large salaries. As of today however, all I see is $1.8 million in compensation to the top two executives of a company that has yet to execute a business model which has shown an ability to increase shareholder value
To be fair, Palatin does have other drugs in their pipeline. And they do spend significant monies on R&D. Despite this, given the lack of revenues, lack of profits and the eventual understanding surrounding who owned which drugs in the June 4th press release, I would not be a buyer of PTN Stock.
he is holding almost 1.5 million shares guess he would like to get this back to 30.00 seems like earnings is gonna be around 2.00 PPS should be closer to 25.00 if that is correct!
The Henry Hub–Mont Belvieu fractionation spread measures the spread between Henry Hub natural gas and Mont Belvieu composite NGLs (natural gas liquids) prices.
Issue Sub Type Common Stock Exchange NASDAQ-GS
52 Week High 15.53 52 Week Low 7.6001
Dividend Yield 0 % Annual Dividend N/A
P/E Ratio 20.11 Shares Outstanding 63,757,553.00
EEP 12:29pm EDT 22.4601 +0.83 +3.84% 22.03 22.615 402,816 1,056,270 8.1768B Sparkline Chart Chart, News, Stats, Options, Board
ETE 12:29pm EDT 14.19 +0.59 +4.34% 13.91 14.50 4,415,079 17,743,200 14.88B Sparkline Chart Chart, News, Stats, Options, Board
ETP 12:29pm EDT 38.94 +1.63 +4.37% 38.10 39.20 1,585,285 3,849,310
are you yapper of 'investor' Investing in PTN has resulted in what? :_)
explain the slow drip down and when was this Co Founded. late 90s and PPS sub FIFTY cents wow big time money must be following :)
ETE ETP CEQP up over 110% and dividends over 10% even with the Brits leaving the EU. look at real healthcare. even your other dog SSH better than this dog. you work for kennel :)
Dec 1, 2010 1.25 1.37 0.84 1.35 1,500 1.35
Nov 1, 2010 1.37 1.48 1.20 1.28 35,000 1.28
Oct 1, 2010 1.62 1.90 1.28 1.37 45,600 1.37
Sep 27, 2010 1: 10 Stock Split
Sep 1, 2010 0.18 1.75 0.17 1.62 62,500 1.62
681 remember buy low sell hi not buy hi hold for 17 years and sell sub 50 cents :)
Medtronic will pay $58 a share, almost double HeartWare’s Friday closing price of $29.98, the company said Monday in a statement. The boards of both companies have unanimously approved the transaction, which is expected to close during Medtronic’s second fiscal quarter ending Oct. 28.
Buying Framingham, Massachusetts-based HeartWare will expand Medtronic’s offerings of diagnostic tools, therapies and services for patients suffering from heart failure. Medtronic estimates that the global market for ventricular-assist devices is about $800 million and will increase by a percentage in the mid-to-high single digits this year and next.
plunges bet it PTN SSH or any other you yap about...:) :)
will Medtronic offer 97% premium on my 48 cents shares of SSH
bought at 7.00 better than Metronic :)